Kornimate/medical-research-clean huggingface dataset:
the effects of a specific exercise program on subjects with cervicogenic headache

Conditions: Cervicogenic Headache

Summary: this study explores with the use of msk ultrasound imaging if the obliquus capitis minor and the rectus capitis major can be contracted with specific exercises.

this study explores if a subject with the neck in full maximal flexion is able to selective contract the the obliquus capitis minor and the rectus capitis major by head extension and rotation while maintaining the spine position. msk ultrasound imaging will be used to measure changes both in length and width.

Eligibility criteria:
inclusion criteria: * no history of surgery, no current neck pain, being able to move the neck actively, being able to read english, between ages 18-65 exclusion criteria: * neck pain, history of surgery, unable to move the head into extension, outside age requirements, unable to read english

Keywords: cervicogenic headache msk ultrasound obliquus capitis minor rectus capitis major exercise
study evaluating myo-029 in adult muscular dystrophy

Conditions: Becker Muscular Dystrophy; Facioscapulohumeral Muscular Dystrophy; Limb-Girdle Muscular Dystrophy

Summary: the purpose of this phase i/ii, multicenter, safety trial is to study myo-029 in adult patients with muscular dystrophy.


Eligibility criteria:
inclusion criteria: * written informed consent. * confirmed clinical and molecular diagnosis of becker muscular dystrophy (bmd), facioscapulohumeral muscular dystrophy (fshd), or limb-girdle muscular dystrophy (lgmd) * independently ambulatory exclusion criteria: * patients with certain clinical conditions * patients using steroids or other medications with the potential to affect muscle function * history of sensitivity to monoclonal antibodies or protein pharmaceuticals * pregnant or lactating women.
promoting appropriate weight gain pregnant women

Conditions: Pregnancy

Summary: the purpose of this study is to learn if engaging in group based phone counseling (gbpc) and an interactive physical activity monitoring system can help pregnant women gain an appropriate amount of weight during pregnancy.


Eligibility criteria:
inclusion criteria: * 12-16 weeks pregnant * pre-pregnancy bmi between 22 kg/m2 to 45 kg/m2 exclusion criteria: * diabetes * pre-eclampsia * hypertension * other metabolic abnormalities

Keywords: gestational weight gain physical activity
rhythmic exercise in older adults with cognitive impairment

Conditions: Cognitive Impairment

Summary: rhythmic physical exercise is a very promising non-pharmaceutical tool to prevent or reduce cognitive decline that occurs in people sixty years of age or older. the main objective is to determine the effect of a rhythmic exercise program on the physical, mental and cognitive performance of older adults with cognitive impairment. the main variables of the study will be: global cognitive function evaluated by the mini mental state examination (mmse) and the montreal cognitive assessment (moca); attention and executive functions evaluated using the trail making test (tmt) part a and b. as secondary variables, the functional abilities evaluated using the senior fitness test (sft) will be taken into account. additionally, sociodemographic variables and variables related to health status will be evaluated. these will take into account the quality of sleep evaluated with the pittsburgh index, the nutritional status evaluated using the mini nutritional assessment-short form (mna-sf) scale, and the stress and anxiety levels will be assessed using the depression anxiety stress scales-21 (dass-21). all variables will be evaluated before the intervention and after it. after the intervention, it is expected that the exercise program will improve the neurocognitive performance, as well as the functional and psychological abilities of older adults.


Eligibility criteria:
inclusion criteria: * be 60 years old or older * do not participate in any physical exercise program * present physical autonomy to participate in the physical activities required by the study. * present scores of \> 25 on the mmse * present current affiliation to the social health security system. * sign the informed consent * understand the instructions, programs and protocols of this project. * complete more than 90% of the intervention with exercise. exclusion criteria: * present medical contraindications for performing physical tests. * present diseases that limit cognitive performance and physical activity. * present vestibular diseases * present rheumatological diseases that can be exacerbated by stress articulate. * refusing to sign the informed consent
f@ce 2.0 - information and communication technology-based rehabilitation intervention after stroke in sweden

Conditions: Stroke

Summary: the purpose of the present proposal is to implement and evaluate a new model for mobile phone supported and family-centred rehabilitation intervention (f@ce 2.0) with regard to functioning in activities in daily living and participation in everyday life among persons with stroke and their families in rural and urban areas in sweden.

the investigators' previous feasibility study suggested beneficial effects on occupational performance and satisfaction of a mobile phone supported and person-centred rehabilitation intervention (f@ce1.0) after stroke in stockholm, sweden. the purpose of the present proposal is to implement and evaluate f@ce 2.0 on functioning in activities in daily living (adl) and participation in everyday life among persons with stroke and their significant others (someone identified by the person with stroke as close i.e.partner, friend, son, daughter). with recommendations on evaluation of complex interventions both outcomes and processes will be studied and hence both quantitative and qualitative methods will be applied. in a randomized controlled trial f@ce 2.0 will be evaluated compared to ordinary rehabilitation in urban/rural sweden regarding; self-efficacy, perceived performance and participation in everyday activities, independence in adl, health care utilization and the families´ perceived participation in everyday activities. qualitative data will explore experiences of people with stroke, significant others and rehabilitation staff of participating in f@ce 2.0. the research project has a multidisciplinary perspective for sustainable rehabilitation interventions, a prerequisite for better participation in everyday life for people with stroke.

Eligibility criteria:
inclusion criteria: * persons who have had a stroke * enrolled in one of the participating home rehabilitation teams in stockholm and dalarna * able to participate in eight weeks of intervention exclusion criteria: * inability to formulate activity goals * inability to express themselves in swedish
the efficacy and safety of tacrolimus in refractory rheumatoid arthritis patients for 6 months and long-term treatment

Conditions: Arthritis, Rheumatoid

Summary: this study is designed to observed prospectively the efficacy and safety of 6 months and long-term treatment of tacrolimus alone or with methotrexate (mtx) in moderate and severe chinese ra patients who shown insufficiency response or intolerance to dmards

this study will enroll 150 cases of refractory rheumatoid arthritis (ra) patients in chinese，who are in moderate or severe disease activity and insufficiency response or intolerance to dmards. the participants plan to be treated with tacrolimus alone, or along with methotrexate (mtx) if participants were tolerant to mtx. the efficacy and safety of 6 month tacrolimus treatment in ra patients will be evaluated with das28 and other disease activity indices.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed based on 1987 acr classification criteria for rheumatoid arthritis; 2. age ≥18 years; 3. patients have a history of dmards including csdmards（methotrexate，leflunomide, hydroxychloroquine, iguratimod, sulfasalazine) or any biologic dmards（tnfi，tocilizumab or tofacitinib），prednisone or chinese traditional medicine（tripterygium glycosides，sinomenine）for 3 months, but couldn't achieve clinical remission， or couldn't tolerate one or more dmards; 4. medium or high disease activity (das28≥3.2); 5. extra-articular manifestations (such as pulmonary fibrosis, proteinuria, leukopenia and peripheral neuropathy ) of ra patients are stable or no significant progress; 6. dose of prednisone and nsaids remain stable for at least one month. exclusion criteria: 1. patients with acute or chronic infections such as active bacterial, viral, fungal, tuberculosis infection or active hepatitis b; 2. platelet counts(plt) \<80 x 10\^9 / l, or white blood cell (wbc) \<3 x 10\^9 / l; 3. propionate acid aminotransferase (alt) or aspartate aminotransferase (ast) is two times higher than the upper limit of normal; 4. renal insufficiency: serum cr ≥ 176 umol / l; 5. pregnant or nursing women (breastfeeding) ； 6. patients has a history of malignancy (cure time in less than 5 years); 7. patients with severe or poorly controlled hypertension, diabetes or cardiac dysfunction; 8. other comorbidities that cannot be treated with immune suppressants. in addition, once patients experience severe adverse drug reactions、ineffective treatment or rapid progression of rheumatoid arthritis, then quit this research.

Keywords: arthritis, rheumatoid tacrolimus treatment outcome safety
t2000 in essential tremor - open label continuation

Conditions: Essential Tremor

Summary: this study will evaluate the safety and efficacy of t2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.

essential tremor (et) is a common form of involuntary shaking not related to parkinson's disease. the medications that are currently used to treat et work in a small proportion of patients and provide only partial improvement in symptoms. use of these current medications is also limited by side-effects in many patients. t2000 is a medication currently under development for the treatment of essential tremor. although t2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. in previous studies, t2000 appeared to be effective in controlling symptoms of et and some patients with severe et had major improvements in tremor. in some patients t2000 was well tolerated for periods up to 5 months and the minimal side-effects seen were those that would be expected for medications in this class. the current study will evaluate the safety and efficacy of t2000 in patients with moderate to severe essential tremor. patients will receive doses of t2000 beginning at 600 mg a day, followed by 800 mg a day and up to 1000 mg a day. the total duration of treatment will be 18 months. patient's tremor and neurological examination will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: patients will be enrolled following completion of a dose escalation trial (such as t2000-0533) * confirmed essential tremor by nih criteria * significant functional activity limitation due to et * patients who have failed, are inadequately treated or cannot tolerate alternative treatments for et as well as treatment naïve patients who have considered but declined alternative treatment exclusion criteria: * patients adequately controlled without side effects on a current et treatment * pregnant patients or patients who may become pregnant during the study * patients with other medical conditions that may cause tremor, such as parkinson's disease or active hyperthyroidism * patients taking medications that might produce tremor or interfere with the evaluation of tremor such as cns-stimulants or beta-blockers * patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders * patients with seizure disorders * patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin * patient with significant general medical or clinical laboratory abnormalities

Keywords: movement disorder
intravenous fish oil in critically ill cardiac patients

Conditions: Coronary Artery Disease

Summary: a large body of evidence has accumulated showing that n-3 pufas exert extensive cardiac effects. the development of commercial solutions of fo opens perspectives for therapeutic applications in patients with acute cardiac conditions.the 3 following hypotheses will be addressed in patients requiring cardiac surgery under cardiopulmonary bypass or after myocardial infarction:perioperative /post-ptca intravenous fish oil modifies the composition of membrane phospholipids in platelets and cardiac cells, blunts the physiological response to cardiac surgery/myocardial infarction, and reduces the incidence of arrhythmias, and reduces the occurrence of systolic dysfunction.

a. randomized trial in 40 cardiac surgery patients early rapid infusion of fish oil (3 times in 24 hours) in cardiac surgery patients. b. randomized trial 20 myocardial infarction patients (abandonned) continuous infusion of the same dose over 24hrs in the myocardial infarction patients additional trial in healthy volunteers (investigating physiological changes after cardiac study): -open trial in 8 healthy lean volunteers to investigate the impact of the same 0.6 g/kg fo dose iv (week 1: 3hrs), and then orally on week 2, on platelet n-3 pufa incorporation, platelet function, heart rate and peak flow response to stress test.

Eligibility criteria:
inclusion criteria: * coronary artery disease requiring elective surgical repair under cardiopulmonary bypass * acute myocardial infarction requiring icu management exclusion criteria: * absence of consent * ventricular ejection fraction \< 35% * beating heart surgery or emergency surgery * hypercholesterolemia \> 5 mmol/l * thrombolysis * chronic steroid therapy * acute or chronic renal failure prior to surgery (plasma creatinine \> 150 umol/l) * chronic coagulation disorder * premenopausal female * consumption of more than 3 times fish per week

Keywords: fish oil supplement n-3 pufa cardiac function membrane incorporation inflammation clinical outcome
a study on the efficacy of 10 mg oral mifepristone for the treatment of symptomatic uterine leiomyomas

Conditions: Leiomyoma

Summary: the first indication of hysterectomies in france are uterine leiomyomas. when they are symptomatic leiomyomas are particularly responsables of an increase of menstruations duration and volume. echography is the reference exam for the diagnosis. it exists two treatments ways:-firstly progestatives and antifibrinolytics for the treatment of hemorragic symptoms, -secondly lh-rh analogs for the treatment of leiomyomas volume and hemorragic symptoms but just used for a small period because of the risk of osteoporosis. different studies with different doses of mifepristone were released. the authors observe a decrease of leiomyomas volume. based on this experience the present placebo controlled study has for objectives:-to confirm the efficacy of 10 mg oral mifepristone during 24 weeks in the volume decrease and in symptoms of leiomyomas, - to assess the safety of the treatment. the aim is to avoid or delay the hysterectomy of non menopausal patients. during the study patients will be evaluated with biological exams, clinical exams, echographies, medical interrogations and their diary cards.


Eligibility criteria:
inclusion criteria: * patients who are willing and able to participate in the study * patients from whom written informed consent has been obtained * patients who contribute to the national insurance scheme * patients with an age between 25 and 49 years old * non menopausal patients * patients who use a non hormonal contraception * patients with one or several , interstitial or subserous, uterine leiomyomas * echographic diameter of leiomyomas must be equal or higher than 30 mm * leiomyomas must be symptomatic
effect of yogurt on minimal hepatic encephalopathy

Conditions: Cirrhosis; Minimal Hepatic Encephalopathy

Summary: the purpose of this study is to determine whether a special yogurt can improve performance on certain tests of intelligence and decrease liver inflammation in patients with cirrhosis.

introduction: cirrhosis is one of the leading causes of death in the united states. minimal hepatic encephalopathy (mhe) is a significant complication of cirrhosis, which is often not treated because of perceived subclinical nature of this condition and the adverse effects and expense of available medications such as lactulose or rifaximin. there is evidence that small intestinal bacterial overgrowth can contribute to the development of mhe and cirrhosis in murine and human studies. probiotics are live bacteria that can modify the indigenous intestinal bacterial flora and have been recently used in the treatment of hepatic encephalopathy in patients with cirrhosis. our aim is to evaluate the effect of probiotic supplementation via yogurt on liver function and inflammatory markers of bacterial translocation and psychometric test performance in cirrhotic patients with mhe in a prospective pilot trial. methods: 30 patients with mhe 2:1 i.e. 20 will be randomized into supplementation with yogurt to be taken 6 ounces twice a day for 60 days and 10 patients will be followed up without yogurt supplementation. all patients will undergo liver function tests, basic metabolic panel, inr, venous ammonia, il-6 and tnf-alpha at baseline, 30 days and at 60 days. all patients will also undergo psychometric testing with number connection test a, digit symbol test, block design and inhibitory control test at baseline and 60 days. regular questioning about adherence to yogurt. collection of yogurt tops as proof of yogurt consumption and review of intake diary will be done at 30 and 60 days from patients randomized to yogurt supplementation. importance: there has been only one human study on the modification of gut flora as a therapeutic tool for improvement of mhe in cirrhosis, however that study included alcoholic liver disease and comprised of chinese patients, therefore etiologies of liver diseases studied were different from those predominant in the united states. since mhe can adversely affect quality of life and overall prognosis, simple, targeted therapies are needed to treat it. we believe that our pilot study will help delineate human gut flora as a definite target for therapy of cirrhosis and mhe and pave the way for future large-scale studies on this subject.

Eligibility criteria:
inclusion criteria: * cirrhosis diagnosed on clinical grounds (within 3 months of enrollment) * mhe diagnosed by abnormalities in a psychometric battery (nct-a,bdt,dst and ict) exclusion criteria: * current or recent (\< 6 month) use of alcohol * co-existing cause of liver dysfunction * use of antibiotics within last 6 weeks * infection or gastrointestinal hemorrhage within the last 6 weeks * hepatocellular carcinoma * psychoactive drug use, including interferon concurrently

Keywords: minimal hepatic encephalopathy cirrhosis
comparison of transdermal and oral estrogens in adolescent girls with ovarian failure

Conditions: Ovarian Failure, Premature

Summary: to directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (turner syndrome) or medical therapies. we hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

treatment with transdermal 17beta(17β) estradiol resulted in higher estradiol levels and more effective feminization compared to oral conjugated equine estrogen but did not result in an otherwise different biochemical profile in this limited number of heterogeneous patients. obe (oral beta estradiol) and tbe (transdermal beta estradiol) provide safe and effective alternatives to ocee (oral conjugated equine estrogen) to induce puberty in girls, but larger prospective randomized trials are required.

Eligibility criteria:
inclusion criteria: in whom initiation of estrogen therapy has been recommended due to ovarian failure * outpatients * age \>=12 years to 17.99 years old exclusion criteria: * spontaneous menses * significant concurrent medical problem including: * liver function tests (lfts) 3 times normal * clotting disorder * ongoing cancer treatment
phase 1-2 trial hcq plus tace in unresectable hcc

Conditions: Hepatocellular Carcinoma

Summary: primary phase i:to determine dose limiting toxicities and maximum tolerated dose (mtd) of the oral administration of hydroxychloroquine (hcq) in conjunction with transarterial chemoembolization (tace) in treating hepatocellular carcinoma (hcc). a conventional 3+3 design will be utilized. primary phase ii: to evaluate the complete response rate in a cohort of patients treated at the mtd, a simon's optimal two-stage design will be utilized.


Eligibility criteria:
inclusion criteria: * patient capable of giving informed consent * patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (pathologically confirmed hcc by biopsy or hcc 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced mri or ct or lesion greater than 2 cm with probable imaging features of hcc and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (afp) greater than 200 mg/ml. * patient not candidate for orthotopic liver transplantation at the hospital of the university of pennsylvania based on review of patient imaging and history at multidisciplinary hepatic tumor conference at the hospital of the university of pennsylvania. * age 18 years old * albumin 2.4 g/dl; total bilirubin 2 mg/dl; inr 1.5 * creatinine 2.0 mg/dl, ast 121 iu/l; alt 189 iu/l * child-turcotte-pugh classification a or b * eastern clinical oncology group performance status 0 or1. exclusion criteria: * prior tace * active gi hemorrhage within 2 weeks of study enrollment * ascites refractory to medical therapy * contraindication to receiving hcq or tace * unilobar hcc * contraindication to contrast enhanced mri (i.e. unable to undergo follow-up imaging) * women who are pregnant * participation in another concurrent treatment protocol

Keywords: outside of transplant criteria